News
![Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new Dexcom ONE Continuous Glucose Monitoring System will
![Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005765/en/
Dr. Alessandro Riva (Photo: Transgene)
Transgene
![Waters Introduces Xevo TQ Absolute – The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Waters Introduces Xevo TQ Absolute – The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer
Waters Corporation (NYSE:WAT) today introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class.i
This press release features multimedia
![STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that the U.S. Food and Drug
![CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
This press release is being re-issued to revise the language in the Selling, General and Administrative bullet under Financial Results. That third bullet, third sentence should read: The net
![Waters präsentiert eine schnellere, zuverlässigere und automatisierte Lösung für die Massen- und Reinheitsanalyse von Biomolekülen](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Waters präsentiert eine schnellere, zuverlässigere und automatisierte Lösung für die Massen- und Reinheitsanalyse von Biomolekülen
Die Waters Corporation (NYSE:WAT) stellte heute neue Software und analytische Säulen zur Unterstützung der Erforschung und Entwicklung von Biomolekülen vor. Mit der neuen App 'Intact Mass' von
![Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity Analysis of Biomolecules](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity Analysis of Biomolecules
Waters Corporation (NYSE:WAT) today introduced new software and analytical columns to aid biomolecule drug discovery and development. The new Waters™ Intact Mass app on waters_connect™ allows
![Dexcom G7 erhält CE-Kennzeichnung – Das kontinuierliche Blutzuckermesssystem der nächsten Generation wird das Diabetesmanagement revolutionieren](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Dexcom G7 erhält CE-Kennzeichnung – Das kontinuierliche Blutzuckermesssystem der nächsten Generation wird das Diabetesmanagement revolutionieren
DexCom, Inc. (NASDAQ:DXCM), der weltweit führende Anbieter im Bereich der kontinuierlichen Blutzuckermessung in Echtzeit für Menschen mit Diabetes, gab heute bekannt, dass das Unternehmen die
![Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark (Conformité Européenne) for the Dexcom G7
![Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
Alacer Corp. today announced the launch of Natean®, a new eco-conscious oral healthcare brand providing products to consumers looking for nature-inspired toothpastes that deliver essential oral
![Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), is pleased to announce that effective March 14 2022, the Ontario government will provide coverage
![Humana Launches CenterWell Home Health](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Humana Launches CenterWell Home Health
One year after launching the CenterWell brand to represent Humana’s payer-agnostic healthcare service offerings, Humana Inc. (NYSE: HUM) has started to transition Kindred at Home’s home health
![Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure’s Founder and Chief Technology Officer, has been selected to receive the 2022 Israel Prize in the field of entrepreneurship and
![NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial unveiling of the CosMx™ Spatial
![Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics for the
![Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq:
![Humana Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Humana Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index
Leading health insurer and health care services company Humana Inc. (NYSE: HUM), proudly announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality
![Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes who are under 18 years old and require ongoing use of
![Charles River Laboratories Announces Wind Contract with Repsol for European Operations](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Charles River Laboratories Announces Wind Contract with Repsol for European Operations
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a wind energy contract with Repsol to address the entirety of the Company’s European power requirements with renewable
![Waters Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Waters Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index
Waters Corporation (NYSE:WAT) announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and
![GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220123005091/en/
Figure 1. Evolution of BCVA In LUMEVOQ®-treated
![AMN Healthcare CEO Susan Salka Recognized as One of 100 Most Influential People by Modern Healthcare](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
AMN Healthcare CEO Susan Salka Recognized as One of 100 Most Influential People by Modern Healthcare
Susan Salka, Chief Executive Officer of AMN Healthcare, was recognized by Modern Healthcare as one of the 100 Most Influential People in Healthcare for 2021, a year of unprecedented stress for
![argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005641/en/
Tim Van Hauwermeiren, co-founder and CEO of argenx
![AMN Healthcare Names Jorge Caballero to Board of Directors](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
AMN Healthcare Names Jorge Caballero to Board of Directors
AMN Healthcare (NYSE: AMN) today announced the Board of Directors has appointed Jorge A. Caballero as a new independent director.
This press release features multimedia. View the full release
![GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005948/en/
Figure 1. Best-Corrected Visual Acuity (BCVA) Change